Skye Bioscience, Inc.
SKYE Nasdaq
SEC CIK 1516551
Follow Skye Bioscience
Weekly email: filings, results
Net income
$69.1K
+100.5% vs same quarter last year
EPS, diluted
$0.01
+100.4% vs same quarter last year
Operating cash flow
−$5.1M
+61.6% vs same quarter last year
Operating income
$26.3K
+100.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$55.9M |
| FY24 | −$26.6M |
| FY23 | −$37.6M |
| FY22 | −$19.5M |
| FY21 | −$8.5M |
| FY20 | −$6.6M |
| FY19 | - |
| FY18 | −$19.2M |
| FY17 | −$3.1M |
| FY16 | −$3.2M |
| FY15 | −$4.8M |
| FY14 | −$2.7M |
| FY13 | −$120.4K |
| FY12 | $4.5K |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$43.1M |
| FY24 | −$26.8M |
| FY23 | −$14M |
| FY22 | −$12.8M |
| FY21 | −$6.6M |
| FY20 | −$6.1M |
| FY19 | - |
| FY18 | −$3.9M |
| FY17 | −$3.4M |
| FY16 | −$3.6M |
| FY15 | −$3.7M |
| FY14 | −$1.8M |
| FY13 | −$63.6K |
| FY12 | - |